Hydroxyurea in Treating Patients With Epstein-Barr Virus-Associated Primary CNS Lymphoma and AIDS

Completed · Phase 2

Conditions studied: Lymphoma

In brief

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of hydroxyurea in treating patients with Epstein-Barr virus-associated primary CNS lymphoma and AIDS.

Key facts

Study ID

NCT00002940

Run by

St. Jude Children's Research Hospital

Starts

1996-10-01

Expected to finish

2002-03-01

Last updated by the study team

2012-10-19

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Louisiana State University Health Sciences Center - Shreveport — Shreveport, Louisiana, United States
• Saint Jude Children's Research Hospital — Memphis, Tennessee, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.